September 2011 in “Urology” Urinary PSA could be an early marker for enlarged prostate.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
March 2011 in “European Urology Supplements” CEC levels may be a useful marker for predicting prostate cancer progression.
October 2010 in “Journal of Men's Health” Larger prostate size in older men may be linked to poorer semen quality and fertility issues.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
February 2007 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.
January 2007 in “El Servicio de Difusión de la Creación Intelectual (National University of La Plata)” Combining D-004 and finasteride is more effective at reducing prostate enlargement than using either alone.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
February 2006 in “Mayo Clinic Proceedings” Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
December 2004 in “SUNScholar (Stellenbosch University)” Certain genetic markers can indicate a person's risk of developing prostate cancer.
January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.
January 2018 in “Repositorio de Tesis - UNMSM” Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.
April 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.
January 2021 in “HAMDAN MEDICAL JOURNAL” Finasteride treats hair loss and reduces prostate cancer risk.
January 2017 in “Indian journal of health sciences and biomedical research KLEU” There is no link between hair loss and prostate enlargement.
March 2013 in “The Journal of Urology” Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.
March 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Hair loss can be an early sign of prostate enlargement.
People with early-onset hair loss (AGA) have a higher risk of heart disease, metabolic syndrome, and prostate enlargement.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
January 2008 in “The Year book of endocrinology” Gene variant linked to prostate cancer, hormone levels, and hair loss.
September 2005 in “Archives of Dermatological Research” Large prostate patients more likely to have hair loss.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
August 2017 in “Revista de la Facultad de Ciencias Médicas (Quito)/Revista de la Facultad de Ciencias Médicas” Early baldness in men may indicate a higher risk of prostate cancer.
April 2012 in “The Journal of Urology” Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.
September 2011 in “Cancer” Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.